Earnings Feed
Start Free
Home/Filings/4/0001171000-17-000041
4//SEC Filing

Nexvet Biopharma plc 4

Accession 0001171000-17-000041

CIK 0001618561operating
View on SEC.govCompany Profile

Filed

Jul 4, 8:00 PM ET

Accepted

Jul 5, 12:18 PM ET

Size

19.2 KB

Accession

0001171000-17-000041

Insider Transaction Report

Form 4
Period: 2017-07-01
Nexvet Biopharma plcNVET
Lismore Damian T.
Chief Financial Officer
Transactions
  • Exercise/Conversion

    Ordinary Shares

    2017-07-01$0.13/sh+13,750$1,719→ 47,500 total
  • Exercise/Conversion

    Restricted Share Units

    2016-09-05−65,000→ 27,500 total
    Exercise: $0.13From: 2017-07-01Exp: 2020-07-01→ Ordinary Shares (13,750 underlying)
  • Exercise/Conversion

    Option to Purchase Shares

    2017-07-01−7,079→ 0 total(indirect: By Spouse)
    Exercise: $0.13From: 2016-11-05Exp: 2023-11-05→ Ordinary Shares (7,079 underlying)
  • Exercise/Conversion

    Option to Purchase Shares

    2017-07-01−4,000→ 0 total
    Exercise: $0.13From: 2017-07-01Exp: 2019-07-01→ Ordinary Shares (4,000 underlying)
  • Exercise/Conversion

    Ordinary Shares

    2017-07-01$0.13/sh+4,000$500→ 67,750 total
  • Exercise/Conversion

    Ordinary Shares

    2017-07-01$0.13/sh+7,079$885→ 21,239 total(indirect: By Spouse)
  • Exercise/Conversion

    Ordinary Shares

    2017-07-01$0.13/sh+16,250$2,031→ 63,750 total
  • Exercise/Conversion

    Restricted Share Units

    2017-07-01−16,250→ 48,750 total
    Exercise: $0.13From: 2017-07-01Exp: 2021-07-01→ Ordinary Shares (16,250 underlying)
Holdings

  • Ordinary Shares

    (indirect: Glenariff Superannuation Pty Ltd <Glenariff Super Fund A/C>)
    18,724
Footnotes (3)
  • [F1]The reporting person and his spouse share voting and dispositive power with respect to these reported securities.
  • [F2]13,750 of the Restricted Share Units vested and became convertible on 7/1/17 and 13,750 of the Restricted Share Units will vest and become convertible on each of 7/1/18 and 7/1/19, in each case subject to payment of the nominal value per share to Issuer within 30 days of vesting.
  • [F3]16,250 of the Restricted Share Units vested and became convertible on 7/1/17 and 16,250 of the Restricted Share Units will vest and become convertible on each of 7/1/18, 7/1/19 and 7/1/20, in each case subject to payment of the nominal value per share to Issuer within 30 days of vesting.

Documents

1 file

Issuer

Nexvet Biopharma plc

CIK 0001618561

→
Entity typeoperating
IncorporatedIreland

Related Parties

1
  • filerCIK 0001618561

Filing Metadata

Form type
4
Filed
Jul 4, 8:00 PM ET
Accepted
Jul 5, 12:18 PM ET
Size
19.2 KB
View on SEC.gov